Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab

BACKGROUND: The CELESTIAL, RESORCE, and REACH‐2 trials showed survival benefit of cabozantinib, regorafenib, and ramucirumab, respectively, in hepatocellular carcinoma (HCC) patients treated with sorafenib who had good performance status (ECOG 0‐1) and liver function (Child‐Pugh‐A). This study chara...

Descripción completa

Detalles Bibliográficos
Autores principales: Fung, Andrea S., Tam, Vincent C., Meyers, Daniel E., Sim, Hao‐Wen, Knox, Jennifer J., Zaborska, Valeriya, Davies, Janine, Ko, Yoo‐Joung, Batuyong, Eugene, Samawi, Haider, Cheung, Winson Y., Lee‐Ying, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333842/
https://www.ncbi.nlm.nih.gov/pubmed/32378799
http://dx.doi.org/10.1002/cam4.3116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333842/
https://www.ncbi.nlm.nih.gov/pubmed/32378799
http://dx.doi.org/10.1002/cam4.3116

Ejemplares similares